This meeting was organised and funded by Novartis Pharmaceuticals Ltd. and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code.

The Novartis Haematology Masterclass is a multidisciplinary educational programme that has been running since 2014 and brings together haematology expertise to provide high-quality educational content. The Masterclass provides a platform for sharing the latest haematology clinical trial data, helping to support the implementation of best clinical practice.

Due to COVID-19 social distancing measures, the 2021 Haematology Masterclass was hosted virtually for the first time ever. Our expert speakers gave presentations on seven haematological disease areas; immune thrombocytopenia (ITP), chronic myeloid leukaemia (CML), acute myeloid leukaemia (AML), myelofibrosis (MF), myelodysplastic syndrome (MDS) with iron overload (IOL), sickle cell disease (SCD) and CAR-T cell therapy in the management of R/R diffuse large B-cell lymphoma (DLBCL). The variety of topics covered is underpinned by the aim that the Novartis Haematology Masterclass should provide broad educational content for healthcare professionals with an interest in haematological disorders.


For an overview of the future of patient care in haematology, please click on the presentation links below.

After viewing a video, you will be eligible to receive your CPD certificate. 
In order to do so, please complete the steps below:

  1. View a video presentation below and watch until the end.
  2. After 100% completion, a pop-up will appear to enable you to download your CPD certificate for each respective presentation.


Prescribing information links can be found underneath each video recording.

Dr Drew Provan and Dr David Kuter discuss and compare the latest 2019 guidelines for immune thrombocytopenia from the International Consensus Report (ICR) and American Society of Hematology (ASH)

The ITP session begins with Dr Provan illustrating the major changes that have occurred in ITP management over the past decade, highlighting themes from the updated ICR 20191 and contextualising this in relation to the ASH 20192 revised guidelines. Dr Kuter expands on these ASH 2019 guidelines describing key recommendations for ITP management, and applying these to example real-world clinical scenarios.

Abbreviations: ASH, American Society of Hematology; ICR, International Consensus Report.

References: 1. Provan D, et al. Blood Adv. 2019;3:3780–817; 2. Neunert C, et al. Blood Adv. 2019;3:3829–66.



Dr Vickie McDonald examines the ITP Registry in the UK and asks, what have we learnt?

Dr McDonald opens with an overview of ITP, its incidence, complex pathophysiology and the challenges involved in ITP management from a UK perspective. After introducing the UKITP Registry, we hear about its key aims, namely to better understand the causes, treatment responses and outcomes in patients with ITP. Dr McDonald provides a top-line tour of the UK recruitment centres, the database and their progress in recruitment. We learn about the UKITP findings so far on treatment usage and platelet response, durability of remission, challenges around the use of splenectomy and ITP management in pregnancy.

Abbreviations: UKITP, UK Immune Thrombocytopenia (Registry).

Dr Dragana Milojkovic updates us with findings from the TARGET-CML study

Dr Milojkovic provides a comprehensive overview of the exciting real-world evidence emerging from the TARGET-CML1 study, including profiling the study design and objectives. Initial results from RQ-PCR testing during the first year on TKIs are examined alongside data on patients who progressed to advanced phase CML. Patient outcomes and treatment pathways for those with optimal, warning or failure responses at ELN milestones are also discussed.

Abbreviations: ELN, European LeukemiaNet; RQ-PCR, real-time quantitative PCR; TKI, tyrosine kinase inhibitor.

Reference: Milojkovic D, et al. Br J Haematol. 2021;192:62–74.


Professor Jane Apperley looks at the management of CML in 2021

Professor Apperley explains how 2020 was a year which saw a number of guidelines updated related to the management of CML. ELN1 and BSH2 guideline recommendations are discussed alongside the latest clinical data, complex patient pathways, diagnostic criteria, additional risk factors and the significance of mutations. Finally, Professor Apperley provides a comprehensive overview of how the management of CML has altered in response to the COVID-19 pandemic.

Abbreviations: BSH, British Society of Haematology; ELN, EuroLeukemiaNet.

References: 1. Hochhaus A, et al. Leukemia. 2020;34(4):966–84. 2. Smith G, et al. Br J Haematol. 2020;191(2):171–93.

Professor Sylvie Freeman provides an overview of minimal residual disease (MRD) in AML

Throughout Professor Freeman’s talk we learn about the value of MRD as a valuable tool for risk stratification and treatment planning. She explores data from recent studies indicating the utility of MRD as a prognostic indicator in AML. She also discusses the link between MRD and risk of relapse and poor survival outcomes.



Professor Sylvie Freeman  

Click here for RYDAPT®▼ (midostaurin) prescribing information


Dr Richard Dillon explores the clinical utility of minimal residual disease (MRD) to support treatment decisions

This relevant and practical presentation from Dr Dillon delves into how MRD monitoring can integrate with cytogenetic and molecular data to inform AML management across the different ELN risk groups. Case study examples highlight how novel and standard diagnostic techniques can optimise patient management, and allow for the early detection and pre-emptive treatment of relapse.

Abbreviations: ELN, European LeukemiaNet.



Dr Richard Dillon 

Click here for RYDAPT®▼ (midostaurin) prescribing information

Professor Baba Inusa highlights the new service configuration for SCD across the UK and the implications of this for clinicians and patients

Haemoglobinopathy service provision in the UK has undergone an extensive review. Professor Inusa takes us through the rationale and objectives for the review, and the new model of service provision from 2019 moving forward. He describes the structure and roles of Haemoglobinopathy Co-ordinating Centres and the National Haemoglobinopathy Panel, what this means for patients, and how these can improve referrals for those eligible for specialist treatment such as HSCT. 

Abbreviations: HSCT, haematopoietic stem cell transplantation.



Dr Emma Drasar provides us with an update on the treatment landscape for SCD

Dr Drasar describes the pathophysiology of SCD and provides an overview of pharmacological approaches to target the underlying disease processes. The role of the P-selectin inhibitor ADAKVEO® (crizanlizumab)▼ in preventing vaso-occlusive crises is described, based on key efficacy and safety findings from the Phase II SUSTAIN1 trial. 

Reference: Ataga KI, et al. N Engl J Med. 2017;376:429–39.



Giselle Padmore-Payne presents practical examples from clinical case scenarios of managing SCD in an adult and a young adult 

Giselle Padmore-Payne provides clinically relevant insights based on her hands-on experience as a nurse specialist. Common complications of SCD are reviewed. She then uses clinical case studies to discuss various treatment options. Finally she describes the burden of SCD in high-income and African countries, with regard to chronic complications and mortality. 


Haematology Masterclass has been running for the past six years and continues to deliver up-to-date and thought-provoking data in the field of haematology. Since 2014, the meeting has brought presentations from leading specialists in the UK and globally.

Our promise

Novartis is truly committed to providing world-class education to our UK healthcare professionals. We recognise the value this meeting brings to a vast range of healthcare professionals including registrars, nurses, pharmacists and consultants. We hope that you can join us for our next meeting in 2022.

Rate this content: 
No votes yet
UK | June 2022 | 112634-1

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]